Patents by Inventor Hisataka Kobayashi

Hisataka Kobayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11075409
    Abstract: A main object of the present disclosure is to provide a stacked battery in which the unevenness of short circuit resistance among a plurality of cells is suppressed.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: July 27, 2021
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Hajime Hasegawa, Yuki Matsushita, Hideaki Nishimura, Yusuke Okuhata, Norihiro Ose, Mitsuru Tateishi, Shigetaka Nagamatsu, Takayuki Uchiyama, Shigenori Hama, Dai Kato, Naohiro Mashimo, Hideyo Ebisuzaki, Ayano Kobayashi, Hisataka Fujimaki
  • Patent number: 11013803
    Abstract: It is shown that CD25-targeted near-infrared photo-immunotherapy causes a unique, rapid and spatially selective depletion of Tregs leading to regression of the treated tumor and inducing systemic immunologic responses in untreated tumors. Based on these observations, provided are compositions and methods of killing immune suppressor cells, for example to treat cancer. Reducing the number of suppressor cells in a subject can remove suppression of effector T cells, for example, to treat cancer using the subject's own immune system. In particular examples, the method includes contacting suppressor cells having a suppressor cell surface protein with an antibody-IR700 molecule, wherein the antibody specifically binds to the suppressor cell surface protein, and in some examples the antibody does not have a functional Fc region. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm, for example at a dose of at least 4 J cm?2.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: May 25, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke, Kazuhide Sato, Noriko Sato
  • Publication number: 20210079112
    Abstract: Provided herein are methods of treating a subject with cancer with a combination of antibody-IR700 molecules and immunomodulators. In particular examples, the methods include administering to a subject with cancer a therapeutically effective amount of one or more antibody-IR700 molecules, where the antibody specifically binds to a cancer cell surface protein, such as a tumor-specific antigen. The methods also include administering to the subject a therapeutically effective amount of one or more immunomodulators (such as an immune system activator or an inhibitor of immuno-suppressor cells), either simultaneously or substantially simultaneously with the antibody-IR700 molecules, or sequentially (for example, within about 0 to 24 hours). The subject or cancer cells in the subject (for example, a tumor or cancer cells in the blood) are then irradiated at a wavelength of 660 to 740 nm at a dose of at least 1 J/cm2.
    Type: Application
    Filed: April 9, 2019
    Publication date: March 18, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Publication number: 20210010914
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Patent number: 10874739
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: December 29, 2020
    Assignee: The Unites States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
  • Patent number: 10830678
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: November 10, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Publication number: 20200121790
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Applicant: The United States of America, as represented by the Secretary Department of Health and Human Service
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
  • Publication number: 20200095331
    Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 26, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Publication number: 20200085950
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 10538590
    Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: January 21, 2020
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 10537641
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: January 21, 2020
    Assignee: The USA as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Publication number: 20190167793
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 6, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
  • Publication number: 20180236076
    Abstract: It is shown that CD25-targeted near-infrared photo-immunotherapy causes a unique, rapid and spatially selective depletion of Tregs leading to regression of the treated tumor and inducing systemic immunologic responses in untreated tumors. Based on these observations, provided are compositions and methods of killing immune suppressor cells, for example to treat cancer. Reducing the number of suppressor cells in a subject can remove suppression of effector T cells, for example, to treat cancer using the subject's own immune system. In particular examples, the method includes contacting suppressor cells having a suppressor cell surface protein with an antibody-IR700 molecule, wherein the antibody specifically binds to the suppressor cell surface protein, and in some examples the antibody does not have a functional Fc region. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm, for example at a dose of at least 4 J cm?2.
    Type: Application
    Filed: August 2, 2016
    Publication date: August 23, 2018
    Applicants: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human, Services
    Inventors: Hisataka Kobayashi, Peter Choyke, Kazuhide Sato, Noriko Sato
  • Publication number: 20170122853
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Application
    Filed: August 7, 2015
    Publication date: May 4, 2017
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Publication number: 20160256564
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: September 28, 2015
    Publication date: September 8, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 9358306
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: June 7, 2016
    Assignee: The United States of America, as rep. by the Secretary, Dept. of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke, Marcelino Bernardo
  • Publication number: 20160015829
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: September 28, 2015
    Publication date: January 21, 2016
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Publication number: 20140120119
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: June 27, 2012
    Publication date: May 1, 2014
    Applicant: The United States of America, as rep. by the Secretary, Dept. of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke, Marcelino Bernardo
  • Publication number: 20130336995
    Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 19, 2013
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke, Makoto Mitsunaga
  • Patent number: 8524239
    Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: September 3, 2013
    Assignee: The United States of America as represented by the Secrectary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke, Makoto Mitsunaga, Marcelino Bernardo